Silodosina Generis 4 mg Cápsula

País: Portugal

Língua: português

Origem: INFARMED (Autoridade Nacional do Medicamento e Produtos de Saúde)

Ingredientes ativos:

Silodosina

Disponível em:

Generis Farmacêutica, S.A.

Código ATC:

G04CA04

DCI (Denominação Comum Internacional):

Silodosina

Dosagem:

4 mg

Forma farmacêutica:

Cápsula

Composição:

Silodosina 4 mg

Via de administração:

Via oral

Unidades em pacote:

Blister 30 unidade(s)

Classe:

7.4.2.1 - Medicamentos usados na retenção urinária

Tipo de prescrição:

MSRM

Grupo terapêutico:

Genérico

Área terapêutica:

silodosin

Indicações terapêuticas:

Duração do Tratamento: Longa Duração

Resumo do produto:

Número de Registo: 5776224 CNPEM: 50118536 CHNM: 10099493 Comercializado

Status de autorização:

Autorizado

Data de autorização:

2019-07-11

Folheto informativo - Bula

$3529$'2(0

,1)$50('


)ROKHWRLQIRUPDWLYR,QIRUPD©¥RSDUDRGRHQWH
6LORGRVLQD*HQHULVPJF£SVXODV
6LORGRVLQD*HQHULVPJF£SVXODV

VLORGRVLQD
/HLDFRPDWHQ©¥RWRGRHVWHIROKHWRDQWHVGHFRPH©DUDWRPDUHVWHPHGLFDPHQWRSRLV
FRQW«PLQIRUPD©¥RLPSRUWDQWHSDUDVL
&RQVHUYHHVWHIROKHWR3RGHWHUQHFHVVLGDGHGHROHUQRYDPHQWH
&DVRDLQGDWHQKDG¼YLGDVIDOHFRPRVHXP«GLFRIDUPDF¬XWLFRRXHQIHUPHLUR
(VWHPHGLFDPHQWRIRLUHFHLWDGRDSHQDVSDUDVL1¥RGHYHG£ORDRXWURV2
PHGLFDPHQWRSRGHVHUOKHVSUHMXGLFLDOPHVPRTXHDSUHVHQWHPRVPHVPRVVLQDLVGH
GRHQ©D
6HWLYHUTXDLVTXHUHIHLWRVLQGHVHM£YHLVLQFOXLQGRSRVV¯YHLVHIHLWRVLQGHVHM£YHLVQ¥R
LQGLFDGRVQHVWHIROKHWRIDOHFRPRVHXP«GLFRIDUPDF¬XWLFRRXHQIHUPHLUR9HUVHF©¥R


2TXHFRQW«PHVWHIROKHWR
2TXH«6LORGRVLQD*HQHULVHSDUDTXH«XWLOL]DGR
2TXHSUHFLVDGHVDEHUDQWHVGHWRPDU6LORGRVLQD*HQHULV
&RPRWRPDU6LORGRVLQD*HQHULV
(IHLWRVLQGHVHM£YHLVSRVV¯YHLV
&RPRFRQVHUYDU6LORGRVLQD*HQHULV
$3529$'2(0

,1)$50('


&RQWH¼GRGDHPEDODJHPHRXWUDVLQIRUPD©·HV

2TXH«6LORGRVLQD*HQHULVHSDUDTXH«XWLOL]DGR
2TXH«6LORGRVLQD*HQHULV"
6LORGRVLQDSHUWHQFHDXPJUXSRGHPHGLFDPHQWRVGHVLJQDGRVSRUEORTXHDGRUHVGRV
UHFHWRUHVDGUHQ«UJLFRVDOID$6LORGRVLQD*HQHULV«VHOHWLYRSDUDRVUHFHWRUHV
ORFDOL]DGRVQDSUµVWDWDEH[LJDHXUHWUD$WUDY«VGREORTXHLRGHVWHVUHFHWRUHVHVWH
FDXVDRUHOD[DPHQWRGRP¼VFXOROLVRGHVWHVWHFLGRV'HVWHPRGRID]FRPTXHVHMD
PDLVI£FLOXULQDUHDOLYLDRVVHXVVLQWRPDV

3DUDTXH«XWLOL]DGR6LORGRVLQD*HQHULV"
6LORGRVLQD*HQHULV«XWLOL]DGRHPKRPHQVDGXOWRVQRWUDWDPHQWRGHVLQWRPDVXULQ£ULRV
DVVRFLDGRVDRDXPHQWREHQLJQRGRYROXPHGDSUµVWDWDKLSHUSODVLDSURVW£WLFDWDLV
FRPR
GLILFXOGDGHHPFRPH©DUDXULQDU
VHQVD©¥RGHQ¥RHVYD]LDUFRPSOHWDPHQWHDEH[LJD
QHFHVVLGDGHPDLVIUHTXHQWHGHXULQDUPHVPR¢QRLWH

2TXHSUHFLVDGHVDEHUDQWHVGHWRPDU6LORGRVLQD*HQH

Características técnicas

$3529$'2(0

,1)$50('


5(6802'$6&$5$&7(567,&$6'20(',&$0(172

120('20(',&$0(172
6LORGRVLQD*HQHULVPJF£SVXODV
6LORGRVLQD*HQHULVPJF£SVXODV

&20326,‰…248$/,7$7,9$(48$17,7$7,9$
6LORGRVLQD*HQHULVPJF£SVXODV
&DGDF£SVXODFRQW«PPJGHVLORGRVLQD
6LORGRVLQD*HQHULVPJF£SVXODV
&DGDF£SVXODFRQW«PPJGHVLORGRVLQD
/LVWDFRPSOHWDGHH[FLSLHQWHVYHUVHF©¥R

)250$)$50$&Œ87,&$
&£SVXOD
6LORGRVLQD*HQHULVPJF£SVXODV
&£SVXODVGHWDPDQKRಫಬFRPFDEH©DGHJHODWLQDEUDQFDHRSDFDJUDYDGDFRPಯ6,/ರH
FRUSRGHJHODWLQDEUDQFDHRSDFDJUDYDGRFRPಯPJರHPWLQWDSUHWDFRQWHQGRXPSµ
EUDQFRDHVEUDQTXL©DGR
6LORGRVLQD*HQHULVPJF£SVXODV
&£SVXODVGHWDPDQKRಫಬFRPFDEH©DGHJHODWLQDEUDQFDHRSDFDJUDYDGDFRPಯ6,/ರH
$3529$'2(0

,1)$50('


FRUSRGHJHODWLQDEUDQFDHRSDFDJUDYDGRFRPಯPJರHPWLQWDSUHWDFRQWHQGRXPSµ
EUDQFRDHVEUDQTXL©DGR

,1)250$‰—(6&/1,&$6
,QGLFD©·HVWHUDS¬XWLFDV
6LORGRVLQD*HQHULV«XWLOL]DGDQRWUDWDPHQWRGRVVLQDLVHVLQWRPDVGDKLSHUSODVLD
EHQLJQDGDSUµVWDWD+%3HPKRPHQVDGXOWRV
3RVRORJLDHPRGRGHDGPLQLVWUD©¥R

3RVRORJLD
$GRVHUHFRPHQGDGD«XPDF£SVXODGHVLORGRVLQDPJSRUGLD(PSRSXOD©·HV
HVSHFLDLVGHGRHQWHV«UHFRPHQGDGDXPDF£SVXODGHVLORGRVLQDPJSRUGLDYHU
DEDL[R
,GRVRV
1¥RV¥RQHFHVV£ULRVDMXVWHVSRVROµJLFRVHPSHVVRDVLGRVDVYHUVHF©¥R

&RPSURPLVVRUHQDO
1¥RV¥RQHFHVV£ULRVDMXVWHVSRVROµJLFRVHPGRHQWHVFRPFRPSURPLVVRUHQDOOLJHLUR
&/&5ุDืPOPLQ5HFRPHQGDVHXPDGRVHLQLFLDOGHPJXPDYH]SRUGLD
HPGRHQWHVFRPFRPSURPLVVRUHQDOPRGHUDGR&/&5ุDPOPLQTXHSRGH
VHUDXPHQWDGDSDUDPJXPDYH]SRUGLDDSµVXPDVHPDQDGHWUDWDPHQWR
GHSHQGHQGRGDUHVSRVWDGHFDGDGRHQWHHPSDUWLFXODU1¥R«UHFRPHQGDGDDXWLOL]D©¥R
HPGRHQWHVFRPFRPSURPLVVRUHQDOJUDYH&/&5POPLQYHUVHF©·HVH
$3529$'2(0